LOGIN  |  REGISTER
Compass Therapeutics

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

August 02, 2023 | Last Trade: US$3.80 0.02 0.53

LOS ANGELES / Aug 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss second quarter 2023 results and provide a general business update on Wednesday, August 9, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior. The dial-in information is as follows:

Date: Wednesday, August 9, 2023
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-330-2446
Conference ID: 4126168
Webcast link: ChromaDex Second Quarter 2023 Earnings Conference Call

The conference call will be broadcast live and will be available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available from 7:30 p.m. ET on Wednesday, August 9, 2023, to 11:59 p.m. ET on Wednesday, August 16, 2023.

Toll-free replay number: 1-800-770-2030
Replay ID: 4126168

About ChromaDex

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB